ALPHANAVI PHARMA
AlphaNavi Pharma specializes in the research and development of new drugs.
ALPHANAVI PHARMA
Industry:
Health Care Pharmaceutical Product Research
Founded:
2019-01-29
Address:
Kyoto, Kyoto, Japan
Country:
Japan
Website Url:
http://www.alphanavi.com
Total Employee:
1+
Status:
Active
Contact:
06-6310-6036
Total Funding:
900 M JPY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx Sitelinks Search Box
Similar Organizations
4D Pharma
4D Pharma PLC is a world leader in the development of live biotherapeutics.
SEP
SEP specializes in the research and development of innovative drugs.
ShouTi
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR.
Supaplants Ltd.
Supaplants Ltd. specializes in the research and development of products.
Yidao Biotechnology
Yidao Biotechnology research and develops vaccines and biomedical products.
Current Employees Featured
Founder
Investors List
Dainippon Sumitomo Pharma
Dainippon Sumitomo Pharma investment in Series A - AlphaNavi Pharma
Nippon Venture Capital
Nippon Venture Capital investment in Series A - AlphaNavi Pharma
SMBC Venture Capital
SMBC Venture Capital investment in Series A - AlphaNavi Pharma
Chushin Venture Capital
Chushin Venture Capital investment in Series A - AlphaNavi Pharma
Kyoto University Innovation Capital
Kyoto University Innovation Capital investment in Series A - AlphaNavi Pharma
Shinsei Capital Partners
Shinsei Capital Partners investment in Series A - AlphaNavi Pharma
Chuo Shinkin Venture Capital
Chuo Shinkin Venture Capital investment in Series A - AlphaNavi Pharma
Official Site Inspections
http://www.alphanavi.com
- Host name: www4124.sakura.ne.jp
- IP address: 133.242.249.34
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "AlphaNavi Pharma"
AlphaNavi Pharma株式会社
AlphaNavi Pharma株式会社（以下、「当社」）（本社：大阪府吹田市、代表取締役社長：小山田 義博）は、シリーズBラウンドの第三者割当増資により総額約6.1億円の資金調達を実施しましたことをお知らせします。 & …See details»
AlphaNavi Pharma - Crunchbase Company Profile
AlphaNavi Pharma is a biotechnology company. They develop a novel analgesic drug for patients suffering from pain, their families, and medical professionals. They are engaged in research and clinical development and create new …See details»
Company - AlphaNavi Pharma株式会社
Apr 1, 2020 AlphaNavi Pharma Inc. has established by Kyoto university, Akita university, Sumitomo Dainippon Pharma Co Ltd., and some investors, whose mission is to develop a …See details»
AlphaNavi Pharma
AlphaNavi Pharma Inc. (“AlphaNavi”) (Head Office: Osaka, Japan; President and CEO: Yoshihiro Oyamada) announce … 2021/05/11. information; AlphaNavi Pharma Inc., Announces Initiation of a Phase 1/2 Clinical Trial of ANP-230 in …See details»
AlphaNavi Pharma Inc. Overview | SignalHire Company Profile
AlphaNavi Pharma is developing a potent and selective voltage-gated sodium channel Nav1.7, Nav1.8 and Nav1.9 inhibitor, ANP-230, for neuropathic pain, including Nav-mutated rare pain …See details»
AlphaNavi Pharma Inc. - VentureRadar
AlphaNavi Pharma Inc. has established by Kyoto university whose mission is to develop a novel analgesic drug for patients suffering from pain, their families, and medical professionals as …See details»
AlphaNavi Pharma - PitchBook
AlphaNavi Pharma General Information Description. Developer of a novel analgesic drug designed to relieve pain for patients suffering from pain. The company's in-house research …See details»
AlphaNavi Pharma - Funding, Financials, Valuation & Investors
AlphaNavi Pharma is a medial company that specializes in the research and development of new drugs. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
ALPHANAVI PHARMA INC. Company Profile - Dun & Bradstreet
ALPHANAVI PHARMA INC. Company Profile | SUITA, OSAKA, Japan | Competitors, Financials & Contacts - Dun & BradstreetSee details»
AlphaNavi Pharma - Overview, News & Similar companies
AlphaNavi Pharma Inc is a company that operates in the Pharmaceuticals industry. It employs 21-50 people and has $1M-$5M of revenue. Is this data correct? View contact profiles from …See details»
Alphanavi Pharma KK - Drug pipelines, Patents, Clinical trials
Explore Alphanavi Pharma KK with its drug pipeline, therapeutic area, technology platform, 1 literature, Disease Domain:Nervous System Diseases, Technology Platform:Small molecule …See details»
AlphaNavi Pharma - Company Profile - Tracxn
Dec 5, 2024 AlphaNavi Pharma is involved in developing therapies for treating neuropathic pain. The lead candidate of the company ANP230, which is a voltage-gated sodium channel …See details»
AlphaNavi Pharma - Contacts, Employees, Board Members
Organization. AlphaNavi Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. …See details»
AlphaNavi Pharma - Products, Competitors, Financials, Employees ...
AlphaNavi Pharma was founded in 2019. Where is AlphaNavi Pharma's headquarters? AlphaNavi Pharma's headquarters is located at 33-94 Enokicho, Suita. What is AlphaNavi Pharma's …See details»
AlphaNavi Pharma - STARTUP DB｜スタートアップデータベース
社名 AlphaNavi Pharma 設立日 2019.01.29 (6年目) 大学発 秋田大学 · 京都大学 住所 〒564-0053 大阪府吹田市江の木町33番94号See details»
AlphaNavi Pharma Established as a Carve-Out Business Venture …
Mar 28, 2019 AlphaNavi is a business venture carved out from Sumitomo Dainippon Pharma that was established in January 2019 by two employees of Sumitomo Dainippon Pharma, with …See details»
AlphaNavi Pharma - Tech Stack, Apps, Patents & Trademarks
AlphaNavi Pharma is a medial company that specializes in the research and development of new drugs. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... These include …See details»
AlphaNavi Pharma Inc., was introduced in the case study of …
Jun 5, 2020 AlphaNavi Pharma Inc., (Head Office: Kyoto, Japan; CEO: Yoshihiro Oyamada), which is a start-up company to develop a novel and innovative analgesic drug for patients …See details»
AlphaNavi Pharma Exercises Option Regarding DSP-3905
Print（PDF/164KB） Oct. 25, 2023 Licensing AlphaNavi Pharma Exercises Option Regarding DSP-3905 under Development for Neuropathic Pain. Sumitomo Pharma Co., Ltd. (Head …See details»
ANP-390 - Drug Targets, Indications, Patents - Synapse - Patsnap
Dec 14, 2024 Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.See details»